1. Differential regulation of HMG-CoA reductase and Insig-1 by enzymes of the ubiquitin-proteasome system.
- Author
-
Tsai YC, Leichner GS, Pearce MM, Wilson GL, Wojcikiewicz RJ, Roitelman J, and Weissman AM
- Subjects
- Acyl Coenzyme A genetics, Acyl Coenzyme A metabolism, Animals, Endoplasmic Reticulum metabolism, Mice, Proteasome Endopeptidase Complex genetics, Proteasome Endopeptidase Complex metabolism, Proteolysis, Sterols metabolism, Ubiquitin genetics, Ubiquitin metabolism, Endoplasmic Reticulum enzymology, Hydroxymethylglutaryl CoA Reductases genetics, Hydroxymethylglutaryl CoA Reductases metabolism, Membrane Proteins genetics, Membrane Proteins metabolism, Receptors, Autocrine Motility Factor genetics, Receptors, Autocrine Motility Factor metabolism
- Abstract
The endoplasmic reticulum (ER)-resident enzyme 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase catalyzes the rate-limiting step in sterol production and is the therapeutic target of statins. Understanding HMG-CoA reductase regulation has tremendous implications for atherosclerosis. HMG-CoA reductase levels are regulated in response to sterols both transcriptionally, through a complex regulatory loop involving the ER Insig proteins, and posttranslationally, by Insig-dependent protein degradation by the ubiquitin-proteasome system. The ubiquitin ligase (E3) gp78 has been implicated in the sterol-regulated degradation of HMG-CoA reductase and Insig-1 through ER-associated degradation (ERAD). More recently, a second ERAD E3, TRC8, has also been reported to play a role in the sterol-accelerated degradation of HMG-CoA reductase. We interrogated this network in gp78(-/-) mouse embryonic fibroblasts and also assessed two fibroblast cell lines using RNA interference. Although we consistently observe involvement of gp78 in Insig-1 degradation, we find no substantive evidence to support roles for either gp78 or TRC8 in the robust sterol-accelerated degradation of HMG-CoA reductase. We discuss factors that might lead to such discrepant findings. Our results suggest a need for additional studies before definitive mechanistic conclusions are drawn that might set the stage for development of drugs to manipulate gp78 function in metabolic disorders.
- Published
- 2012
- Full Text
- View/download PDF